Seeking Alpha
 

Celgene Corporation (CELG)

- NASDAQ
  • Jun. 12, 2013, 8:11 AM
    Celgene's (CELG +1.6%) board has authorized the repurchase of up to an extra $3B in shares, having exhausted a previous $2.5B buyback program. So far this year, the company has repurchased $1.8B in stock. (See apremilast results) (PR)
    | Comment!
  • Jun. 12, 2013, 8:04 AM
    Celgene (CELG) says 52-week results demonstrate apremilast produces "meaningful improvements" in ACR scores for patients with psoriatic arthritis. The company will present the data at the European Congress of Rheumatology later today. SA contributor Todd Campbell says the drug "offers upside" for CELG shares and notes that "analysts expect apremilast may generate sales of $300-500M/year." Shares +1.5% premarket.
    | Comment!
  • Jun. 11, 2013, 8:40 AM
    Biotech startup Agios Pharmaceuticals has filed to raise $86M in an IPO. The company has raised over a quarter of a billion dollars from VC firms and Celgene (CELG), which has invested $37.5M and made $141.2M in collaboration payments. Celgene has also committed to buying stock in the IPO. Agios has been developing a new approach to treating cancer and metabolic diseases, but has yet to start clinical trials for any of its drug candidates. (S1)
    | 1 Comment
  • Jun. 5, 2013, 3:07 PM
    Celgene (CELG -4.3%) gets FDA approval for its supplemental new drug application for Revlimid to treat mantle cell lymphoma. The drug is already cleared for multiple myeloma, another white blood cell cancer. Analysts estimate the drug could generate around $5.9B in sales in 2016.
    | 3 Comments
  • Jun. 3, 2013, 10:57 AM
    Celgene (CELG -1.5%) trades lower after presentations at ASCO. The company says high-dose chemotherapy and tandem autologous stem cell transplant demonstrated longer median progression-free survival and overall survival than REVLIMID, melphalan, and prednisone. However, a maintenance analysis showed followup treatments with REVLIMID increased progression-free survival and overall survival. (PR)
    | 1 Comment
  • May 31, 2013, 8:16 AM
    The EMA's Committee for Medicinal Products for Human Use (CHMP) gives its blessing to Celgene's (CELG) oral multiple myeloma treatment pomalidomide based on data from a Phase 3 trial. The committee also adopts a positive opinion for Aegerion's (AEGR) HoFH treatment LOJUXTA and says new data does not support the contention that Sanofi's (SNY) Lantus increases the risk of cancer. AEGR + 0.92% premarket.
    | Comment!
  • May 23, 2013, 7:54 AM
    The FDA grants priority review to Celgene's (CELG) NDA for the supplemental use of ABRAXANE alongside gemcitabine for patients with advanced pancreatic cancer. (PR)
    | 1 Comment
  • May 16, 2013, 1:49 PM
    Biotech names are weak today on the back of several ASCO data presentation releases: REGN -2.3%, ALXN -4.2%, VRTX -2.3%, CELG -4.5%, ARRY -2.2%, AMGN -1.4%.
    | 1 Comment
  • May 6, 2013, 3:09 PM
    Celgene (CELG +0.5%) says Apremilast achieves statistical significance for its primary endpoint in the first company-sponsored study of psoriatic arthritis patients who had not previously received oral DMARDs. This is the fourth randomized Phase III study of the treatment to show promising results. Last month, Deutsche Bank called the drug a potential "blockbuster" in a note accompanying an upgrade.
    | 2 Comments
  • Apr. 26, 2013, 8:53 AM
    Celgene (CELG) says based on a Phase III trial, the Committee for Medicinal Products for Human Use has recommended REVLIMID for approval regarding the treatment of transfusion-dependent anemia due to MDS when other therapies aren't sufficient or prove inadequate. Shares +.85% premarket after falling marginally Thursday following Q1 results.
    | Comment!
  • Apr. 25, 2013, 8:01 AM
    More on Celgene (CELG) Q1 earnings: REVLIMD sales +16% Y/Y to $1B, light of consensus of $1.1B. ABRAXANE sales of $123M and VIDAZA of $204M inline. SG&A expenses of $333M, +11.3%. Purchased approximately 4.2M shares at cost of $403M (average price $95.95). FY2013 EPS guidance raised to $5.55-$5.65 from $5.50-$5.60. Shares -0.9% premarket. Conference call at 9 ET. (PR)
    | Comment!
  • Apr. 25, 2013, 7:30 AM
    Celgene (CELG): Q1 EPS of $1.37 beats by $0.01. Revenue of $1.46B (+15% Y/Y) misses by $0.01B. (PR)
    | Comment!
  • Apr. 25, 2013, 12:05 AM
    Notable earnings before Thursday’s open: ABC, AIXG, ALK, ALXN, AME, ASPS, AVT, AZN, BC, BG, BIIB, BLL, BMS, BMY, BSX, BWA, CAB, CAM, CCE, CELG, CFX, CL, CMS, CNX, COP, CRR, CSH, D, DAN, DLX, DNKN, DO, DOW, DST, EQT, ESI, ETR, FAF, GPK, GTI, GTLS, HERO, HOG, HP, HSY, IDCC, IMAX, JBLU, KKR, KMT, LEA, LINE, LKQ, LLL, LUV, LVLT, MDP, MJN, MMM, MO, NBL, NLSN, NMM, NYT, O, ODFL, ORI, OXY, PCS, PDS, PH, PHM, POT, PRLB, PTEN, PVR, RCL, RDWR, RRD, RS, RTN, RYN, SCG, SIAL, SUI, SWK, SWY, TASR, TSRA, TWC, UAL, UPS, UTHR, WBC, XOM, YNDX, ZMH
    | Comment!
  • Apr. 24, 2013, 5:30 PM
    Notable earnings before Thursday’s open: ABC, AIXG, ALK, ALXN, AME, ASPS, AVT, AZN, BC, BG, BIIB, BLL, BMS, BMY, BSX, BWA, CAB, CAM, CCE, CELG, CFX, CL, CMS, CNX, COP, CRR, CSH, D, DAN, DLX, DNKN, DO, DOW, DST, EQT, ESI, ETR, FAF, GPK, GTI, GTLS, HERO, HOG, HP, HSY, IDCC, IMAX, JBLU, KKR, KMT, LEA, LINE, LKQ, LLL, LUV, LVLT, MDP, MJN, MMM, MO, NBL, NLSN, NMM, NYT, O, ODFL, ORI, OXY, PCS, PDS, PH, PHM, POT, PRLB, PTEN, PVR, RCL, RDWR, RRD, RS, RTN, RYN, SCG, SIAL, SUI, SWK, SWY, TASR, TSRA, TWC, UAL, UPS, UTHR, WBC, XOM, YNDX, ZMH
    | Comment!
  • Apr. 22, 2013, 8:02 AM
    Celgene (CELG) +1.8% premarket as Cantor Fitzgerald reiterates the stock a Buy and raises its price target to $142.
    | Comment!
  • Apr. 5, 2013, 8:13 AM
    Celgene (CELG) gets an upgrade from Deutsche Bank to Buy from Hold. The bank says survey data gathered from 100 dermatologists and rheumatologists suggests Apremilast is a "blockbuster." DB raises its price target from $105 to $143. Shares +1.4% premarket.
    | 2 Comments
Visit Seeking Alpha's
CELG vs. ETF Alternatives
Company Description
Celgene Corp is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.
Sector: Healthcare
Industry: Biotechnology
Country: United States